전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved104 programs
CGTLimited DatastaleCaribou Biosciences, Inc.Preclinical

Caribou-sponsored investigational therapy (Caribou-sponsored investigational therapy)

Lymphoma, Non-Hodgkin; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells (Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBenjamin TomlinsonPhase 1

Fully human anti CD19 CAR-T Cell Dose (Fully human anti CD19 CAR-T Cell Dose)

Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

GB5005 CART (GB5005 CART)

Non-hodgkin Lymphoma; Refractory Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleChangchun GeneScience Pharmaceu…Phase 1

Gentulizumab (Gentulizumab)

Solid Tumor; Non-Hodgkin Lymphoma · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#Non-HodgkinLymphoma+1
Trials 1Status Discontinued
CGTLimited DatastaleImmune Cell, Inc.Phase 1

ICAR30 T cells (ICAR30 T cells)

Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) single-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShanghai JW Therapeutics Co., L…Phase 1

JWCAR239 (JWCAR239)

B-Cell Non-Hodgkin Lymphoma; Large B Cell Diffuse Lymphoma · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

LV20.19 CAR T cells (LV20.19 CAR T cells)

Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
ADCLimited DatastaleMethylGene Inc.Phase 2

brentuximab vedotin (Adcetris, Mocetinostat Plus Brentuximab Vedotin)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#antibody-drug-conjugate#MethylGene
Trials 1Status Active
CGTLimited DatastaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleTimmune Biotech Inc.Phase 1

Novel CAR-T (Novel CAR-T)

B-cell Non Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

ONC-PluReceptor NK cells (ONC-PluReceptor NK cells)

Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 1

G (Obinutuzumab, Obinutuzumab (G))

B-Cell Lymphoma; Non-Hodgkin Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase1#monoclonal-antibody#Non-HodgkinLymphoma+1
Trials 1Status Active
CGTLimited DatastaleVittoria BiotherapeuticsPhase 1

Senza5 CART5 (Senza5 CART5)

T Cell Non-Hodgkin Lymphoma · T Cell Non-Hodgkin Lymphoma

#TCellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T))

Non-hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART7 cells (ThisCART7 cells)

T-Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-Acute Lymphoblastic Leukemia

#T-AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleTimmune Biotech Inc.Phase 2

TriCAR-T-CD19 (TriCAR-T-CD19)

Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active

5 / 6 pages

← PreviousNext →